Article

New surface ablation approach shows advantages over PRK

Advanced surface ablation using the MEL 80 laser (ASA80, Carl Zeiss Meditec) showed significant advantages compared with conventional PRK, especially for the recovery of best-corrected visual acuity (BCVA), pain, and haze formation.

Paris—Advanced surface ablation using the MEL 80 laser (ASA80, Carl Zeiss Meditec) showed significant advantages compared with conventional PRK, especially for the recovery of best-corrected visual acuity (BCVA), pain, and haze formation.

Sven Lee, MD, of Nurnberg, Germany, present clinical results of a cohort study regarding this new approach to excimer-laser-surface ablation for myopia in a free paper presentation at the European Society of Cataract and Refractive Surgeons meeting. Dr. Lee and colleagues evaluated the differences between the modalities, considering uncorrected visual acuity (UCVA), BCVA, stability, predictability, pain, re-epithelialization and haze formation in patients.

The study, conducted between January 2003 and April 2004, looked at 176 eyes of 116 patients treated with the ASA80 laser and 358 eyes of 225 patients treated with PRK. The spot-scanning laser MEL 80 was used in both groups. Follow-up was conducted after 1 and 4 weeks, as well as 6 and 12 months.

The mean preoperative spherical equivalent for the ASA80 group was –5.67 D ± 2.85, with myopia at –1 to –12.75 D and astigmatism at –0.25 to –6.50 D. For the PRK group, spherical equivalent was –5.59 D ± 2.79 D, with myopia at –0.75 to –13.25 D and astigmatism at –0.025 to –6.50 D.

Dr. Lee pointed that after 1 year, predictability, safety, and stability were better in the ASA80 group. Mean postoperative pain, haze formation, and re-epithelialization time in the ASA80 group also were better. There were no differences in the area of efficacy.

After 1 and 4 weeks postoperative, UCVA, BCVA, and recovery of BCVA were significantly better in the ASA80 group. In the 6- and 12-month follow-up, no significant differences between the two groups were found. UCVA in both groups after 6 and 12 months was better than preoperative BCVA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.